Jim Cramer on IQVIA: "I Like the Business Very Much, I Just Don't Know Whether This Is the Right Stock to Play It"

IQVIA Holdings Inc. (NYSE:IQV) is one of the S&P 500 stocks that Jim Cramer shared his take on. Cramer called it a “great business,” as he said:

Finally, the ninth-worst performing stock in the S&P 500 was IQVIA, down 22.3%. Now, this is a CRO, a contract research organization. Pharmaceutical companies hire these guys to run their clinical trials. Oh, what a great business. The CROs were all caught up in the AI displacement trade, unfairly, in my opinion. I just don’t see that happening at all. When IQVIA reported in early February, although, the company reported a solid beat, but also gave a weaker than expected full-year forecast.

Now, I know it doesn’t help that RFK Junior’s FDA is taking a skeptical approach toward new drugs, particularly orphan drugs, by the way. Overall, with expectations now reset, I am tempted to say that you’re probably getting a nice buying opportunity here. But this is another company where any potential buyers will be swimming upstream. I like the business very much. I just don’t know whether this is the right stock to play it.

IQVIA Holdings Inc. (NYSE:IQV) provides clinical research and data analytics to the healthcare and life sciences industries. The company assists pharmaceutical and biotech companies by managing clinical trials, providing laboratory services, and tracking sales and patient engagement.

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.  Follow Insider Monkey on Google News.